Skip to main content

Table 1 Association analysis in New Zealand case-control sample sets

From: The renal urate transporter SLC17A1 locus: confirmation of association with gout

SNP a Cases MAF Controls MAF P unadjusted P adjusted b OR (95% CI) HWE case HWE control
rs1165196 TT CT CC C TT CT CC C      
Caucasian 167 (0.400) 201 (0.482) 49 (0.118) 0.359 389 (0.318) 590 (0.482) 246 (0.200) 0.442 1.0 × 10-4 5.5 × 10-5 0.71 (0.60 to 0.83) 0.33 0.41
   EP/N 130 (0.570) 86 (0.377) 12 (0.053) 0.241 98 (0.516) 77 (0.405) 15 (0.079) 0.282 0.19 0.26 0.81 (0.60 to 1.11) 0.65 0.98
   EP/Z 16 (0.364) 22 (0.500) 6 (0.136) 0.386 53 (0.358) 64 (0.432) 31 (0.209) 0.426 0.51 0.88 0.85 (0.52 to 1.38) 0.72 0.16
   WP 138 (0.556) 99 (0.399) 11 (0.044) 0.244 69 (0.496) 54 (0.388) 16 (0.115) 0.309 0.05 0.06 0.72 (0.52 to 1.00) 0.20 0.28
   EP/WP 10 (0.667) 5 (0.333) 0 (0.000) 0.167 6 (0.316) 10 (0.526) 3 (0.158) 0.421 0.02 0.07 0.28 (0.09 to 0.87) 0.33 0.73
Combinedc          5.7 × 10-7   0.72 (0.64 to 0.82)   
rs1183201 d TT TA AA A TT TA AA A      
Caucasian 158 (0.384) 205 (0.499) 48 (0.117) 0.366 356 (0.291) 608 (0.496) 261 (0.213) 0.461 2.0 × 10-6 3.0 × 10-6 0.67 (0.57 to 0.79) 0.13 0.89
   EP/N 130 (0.570) 86 (0.377) 12 (0.053) 0.241 96 (0.505) 78 (0.411) 16 (0.084) 0.289 0.11 0.14 0.78 (0.57 to 1.06) 0.65 0.98
   EP/Z 15 (0.349) 21 (0.488) 7 (0.163) 0.407 52 (0.349) 61 (0.409) 36 (0.242) 0.446 0.49 0.95 0.85 (0.52 to 1.39) 0.94 0.04
   WP 132 (0.543) 101 (0.416) 10 (0.041) 0.249 68 (0.479) 57 (0.401) 17 (0.120) 0.320 0.03 0.03 0.70 (0.51 to 0.97) 0.08 0.35
   EP/WP 9 (0.600) 6 (0.400) 0 (0.000) 0.200 7 (0.350) 10 (0.500) 3 (0.150) 0.400 0.07 0.11 0.38 (0.13 to 1.12) 0.25 0.99
Combinedc          3.0 × 10-8   0.70 (0.62 to 0.79)   
rs9358890 AA AG GG G AA AG GG G      
Caucasian 366 (0.884) 47 (0.114) 1 (0.002) 0.059 1114 (0.912) 104 (0.085) 4 (0.003) 0.046 0.12 0.17 1.31 (0.93 to 1.85) 0.69 0.35
   EP/N 97 (0.418) 99 (0.427) 36 (0.155) 0.369 80 (0.419) 78 (0.408) 33 (0.173) 0.377 0.80 0.71 0.96 (0.73 to 1.28) 0.21 0.07
   EP/Z 34 (0.753) 11 (0.244) 0 (0.000) 0.122 129 (0.827) 26 (0.167) 1 (0.006) 0.090 0.44 0.42 1.41 (0.67 to 2.96) 0.35 0.80
   WP 110 (0.440) 101 (0.404) 39 (0.156) 0.358 73 (0.507) 61 (0.424) 10 (0.069) 0.281 0.03 0.06 1.43 (1.04 to 1.95) 0.06 0.57
   EP/WP 8 (0.533) 7 (0.467) 0 (0.000) 0.233 12 (0.571) 7 (0.333) 2 (0.095) 0.262 0.78 0.87 0.86 (0.29 to 2.55) 0.24 0.53
Combinedc          0.05   1.19 (1.00 to 1.41)   
rs3799344 CC CT TT T CC CT TT T      
Caucasian 165 (0.404) 193 (0.473) 50 (0.123) 0.359 379 (0.309) 592 (0.483) 255 (0.207) 0.450 5.9 × 10-6 2.8 × 10-5 0.69 (0.58 to 0.81) 0.58 0.38
   EP/N 128 (0.561) 88 (0.386) 12 (0.053) 0.246 97 (0.524) 73 (0.395) 15 (0.081) 0.278 0.46 0.37 0.84 (0.62 to 1.15) 0.53 0.80
   EP/Z 17 (0.378) 22 (0.489) 6 (0.133) 0.378 53 (0.353) 64 (0.427) 33 (0.220) 0.433 0.35 0.72 0.79 (0.49 to 1.29) 0.79 0.49
   WP 136 (0.551) 98 (0.397) 13 (0.053) 0.251 64 (0.457) 59 (0.421) 17 (0.121) 0.332 0.02 0.02 0.67 (0.49 to 0.93) 0.39 0.55
   EP/WP 10 (0.667) 5 (0.333) 0 (0.000) 0.167 7 (0.350) 10 (0.500) 3 (0.150) 0.400 0.04 0.08 0.30 (0.10 to 0.95) 0.44 0.85
Combinedc          7.4 × 10-8   0.71 (0.62 to 0.80)   
rs12664474 AA AG GG G AA AG GG G      
Caucasian 264 (0.632) 134 (0.321) 20 (0.048) 0.208 867 (0.707) 321 (0.262) 38 (0.031) 0.162 0.01 1.2 × 10-3 1.36 (1.12 to 1.66) 0.57 0.22
   EP/N 90 (0.383) 104 (0.443) 41 (0.174) 0.396 74 (0.392) 77 (0.407) 38 (0.201) 0.405 0.79 0.17 0.96 (0.73 to 1.27) 0.25 0.03
   EP/Z 25 (0.543) 18 (0.391) 3 (0.065) 0.261 107 (0.704) 39 (0.257) 6 (0.039) 0.168 0.05 0.13 1.75 (1.00 to 3.05) 0.92 0.32
   WP 102 (0.411) 106 (0.427) 40 (0.161) 0.375 63 (0.444) 67 (0.472) 12 (0.085) 0.320 0.13 0.10 1.27 (0.93 to 1.73) 0.16 0.32
   EP/WP 7 (0.467) 6 (0.400) 2 (0.133) 0.333 12 (0.571) 7 (0.333) 2 (0.095) 0.262 0.51 0.38 1.41 (0.51 to 3.92) 0.70 0.53
Combinedc          2.0 × 10-3   1.25 (1.09 to 1.43)   
  1. CI, confidence interval; HWE, MAF, OR, odds ratio. aGenotyping success rate: rs1165196 Caucasian, Eastern Polynesian (EP), Western Polynesian (WP) and EP/WP - cases 99.0%, 95.8%, 98.8% and 100%, respectively, controls 99.8%, 96.8%, 96.5% and 90.5%, respectively; rs1183201 Caucasian, EP, WP and EP/WP - cases 97.6%, 95.4%, 96.8% and 100%, respectively, controls 99.7%, 97.1%, 98.6% and 95.2%, respectively; rs9358890 Caucasian, EP, WP and EP/WP - cases 98.3%, 97.5%, 99.6% and 100%, respectively, controls 99.2%, 99.4%, 100% and 90.5%, respectively; rs3799344 Caucasian, EP, WP, EP/WP - cases 96.9%, 96.1%, 98.4% and 100%, respectively, controls 99.8%, 96.0%, 97.2% and 95.2%, respectively; rs12664474 Caucasian, EP, WP, EP/WP - cases 99.3%, 98.9%, 98.8% and 100%, respectively, controls 99.8%, 97.7%, 98.6% and 100%, respectively. bAdjusted for sex. cMeta-analysis by the Mantel-Haenszel method. Breslow-Day test for heterogeneity: rs1165196, P = 0.45; rs1183201, P = 0.75; rs9358890, P = 0.77; rs3799344, P = 0.58; rs12664474, P = 0.97. dPopulation attributable risk (the reduction in gout incidence if the risk variant was absent) for positivity of the risk (T) allele of rs1183201 is 38.2% for Caucasian, 21.4% for EP/N, 27.3% for EP/N and 41.3% for WP.